THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 19 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $11,517,000,000 | – | 10,000,000 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 13,473,000 | $12,756,000 | 1.74% |
| Shaolin Capital Management LLC | 14,065,000 | $13,281,000 | 0.93% |
| ZAZOVE ASSOCIATES LLC | 3,773,000 | $3,584,000 | 0.44% |
| FARALLON CAPITAL MANAGEMENT LLC | 56,695,000 | $53,806,000 | 0.32% |
| Baupost Group | 30,000,000 | $28,396,000 | 0.26% |
| Aequim Alternative Investments LP | 3,000,000 | $2,840,000 | 0.21% |
| WOLVERINE ASSET MANAGEMENT LLC | 24,100,000 | $22,817,000 | 0.17% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 5,500,000 | $5,257,000 | 0.15% |
| SSI INVESTMENT MANAGEMENT LLC | 1,750,000 | $1,648,000 | 0.12% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 430,000 | $406,000 | 0.06% |